<DOC>
	<DOCNO>NCT03061214</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe South America . The aim trial compare effect once-weekly dosing two dose level semaglutide versus sitagliptin 100 mg once-daily glycaemic control 30 week treatment . Subjects remain stable pre-trial metformin .</brief_summary>
	<brief_title>Efficacy Safety Semaglutide Once-weekly Versus Sitagliptin Once-daily add-on Metformin Subjects With Type 2 Diabetes ( SUSTAIN - CHINA MRCT )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male female , age equal 18 year time signing informed consent Subjects diagnose type 2 diabetes stable treatment period 60 day prior screen metformin equal 1500 mg ( maximum tolerate dose equal 1000 mg ) . Stable define unchanged medication unchanged daily dose HbA1c 7.0 10.5 % ( 5391 mmol/mol ) ( inclusive ) Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method throughout trial include 5 week followup period ( adequate contraceptive measure require local regulation practice ) Any disorder , opinion investigator , might jeopardise subject 's safety compliance protocol Treatment glucose lower agent ( ) state inclusion criterion period 60 day screen . An exception shortterm treatment ( equal 7 day total ) insulin connection intercurrent illness History chronic idiopathic acute pancreatitis Screening calcitonin value equal 50 ng/L ( pg/mL ) Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia syndrome type 2 ( MEN 2 ) Impaired renal function define estimate glomerular filtration rate ( eGFR ) 60 ml/min/1.73 m^2 per modification diet renal disease ( MDRD ) formula ( 4 variable version ) Acute coronary cerebrovascular event within 90 day randomisation Heart failure , New York Heart Association ( NYHA ) class IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>